Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

FDA Clears First Drug To Treat Phenylketonuria

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

BioMarin estimates Kuvan revenue of $57,000 per patient per year.

You may also be interested in...



BioMarin Tightens Loose Rivets On Bridge To Wider PKU Market

Firm corrects bad numbers for Kuvan new-patient starts ahead of early results with second – and maybe bigger – market player, PEG-PAL

BioMarin Tightens Loose Rivets On Bridge To Wider PKU Market

Firm corrects bad numbers for Kuvan new-patient starts ahead of early results with second – and maybe bigger – market player, PEG-PAL

BioMarin Takes Steps To Drive Kuvan Uptake

Ultra-orphan PKU therapy touted through registry, free trials and clinic-based town hall meetings.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works

ADHD Drugs: FDA Commissioner Blames Inappropriate Prescribing For Shortages

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

See All
UsernamePublicRestriction

Register

PS065509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By